Breaking News
0

Eyepoint Pharmaceuticals Inc (EYPT)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Eyepoint Pharma's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.470 +0.120    +8.89%
15:59:59 - Closed. Currency in USD ( Disclaimer )
Type: Equity
Market: United States
ISIN: US30233G1004 
CUSIP: 30233G100
  • Volume: 1,042,914
  • Bid/Ask: 1.350 / 1.510
  • Day's Range: 1.340 - 1.540
START TRADING NOW
| AD | 75% of retail investor accounts lose money when trading spread bets and CFDs with this provider
Eyepoint Pharma 1.470 +0.120 +8.89%
START TRADING NOW
| AD | 75% of retail investor accounts lose money when trading spread bets and CFDs with this provider

EYPT Overview

 
This is the main Eyepoint Pharmaceuticals Inc stock chart and current price. You can find more details by going to one of the sections under this page such as historical data, charts, technical analysis and others.
Loading
Last Update:
  • 1 Day
  • 1 Week
  • 1 Month
  • 3 Months
  • 6 Months
  • 1 Year
  • 5 years
  • Max
Prev. Close1.35
Day's Range1.34 - 1.54
Revenue12.15M
Open1.38
52 wk Range1.19 - 2.824
EPS - 0.85
Volume1,042,914
Market Cap158.93M
Dividend (Yield)N/A (N/A)
Average Vol. (3m)489,274
P/E RatioN/A
Beta1.72
1-Year Change - 37.21%
Shares Outstanding108,117,440
Next Earnings DateMar 12, 2020
What is your sentiment on Eyepoint Pharma?
or
Market is currently closed. Voting is open during market hours.

Eyepoint Pharmaceuticals Inc News


EyePoint Pharma up 8% on U.S. launch of YUTIQ
EyePoint Pharma up 8% on U.S. launch of YUTIQ By Seeking Alpha - Feb 04, 2019

EyePoint Pharmaceuticals (NASDAQ:EYPT) has commercially launched YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg in the U.S. for the treatment of chronic non-infectious...

EyePoint up 8% premarket on U.S. launch of Yutiq
EyePoint up 8% premarket on U.S. launch of Yutiq By Seeking Alpha - Feb 04, 2019

EyePoint Pharmaceuticals (NASDAQ:EYPT) is up 8% premarket on light volume on the heels of its U.S. commercial launch of YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg...

Eyepoint Pharmaceuticals Inc Analysis


Technical Summary

Type 5 mins 15 mins Hourly Daily Monthly
Moving Averages Buy Buy Sell Sell Strong Sell
Technical Indicators Strong Sell Strong Sell Strong Buy Strong Sell Strong Sell
Summary Neutral Neutral Neutral Strong Sell Strong Sell

Candlestick Patterns

 

Filter Table By:

Candle Sticks Characteristics:

Time Frame
Type
Pattern Indication
Reliability
Pattern Timeframe Reliability Candles Ago Candle Time
Emerging Patterns
Abandoned Baby Bullish 15 Current
Belt Hold Bullish 15 Current
Bullish Engulfing 15 Current
Morning Doji Star 15 Current
Morning Star 15 Current
Belt Hold Bullish 30 Current
Bullish doji Star 1W Current
Harami Cross 1W Current
Engulfing Bearish 1M Current
Completed Patterns
Bullish doji Star 15 1 Nov 13, 2019 03:30PM
Bullish Engulfing 30 3 Nov 13, 2019 02:00PM
Doji Star Bearish 1W 5 Oct 06, 2019

Eyepoint Pharmaceuticals Inc Quotes

Exchange Last Bid Ask Volume Change % Currency Time
  NASDAQ 1.470 1.350 1.510 1,042,914 +8.89% USD 15:59:59  
  OTC Markets 1.990 0.000 0.000 0 0.00% USD 16/06  
  Berlin 1.260 1.280 1.400 0 +5.00% EUR 11:42:00  
  Munich 1.210 0.000 0.000 0 +6.14% EUR 02:00:00  
  Frankfurt 1.210 1.310 1.360 0 +6.14% EUR 03:15:00  
  Stuttgart 1.150 1.554 1.615 0 0.00% EUR 12/11  

Trending Stocks

Create Alert
Add to Portfolio
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

  Name Last High Low Chg. Chg. % Vol. Time
  Apple 264.47 264.78 261.07 +2.51 +0.96% 25.62M 15:59:59  
  Facebook 193.19 195.70 192.74 -1.28 -0.66% 10.83M 15:59:59  
  Alphabet A 1,296.18 1,302.52 1,292.15 -1.03 -0.08% 1.02M 15:59:59  
  Microsoft 147.31 147.46 146.28 +0.24 +0.16% 16.85M 15:59:59  
  Walt Disney 148.72 149.92 136.84 +10.14 +7.32% 45.63M 15:59:59  
  Tesla 346.11 356.33 345.18 -3.82 -1.09% 8.41M 15:59:59  
  Cisco 48.46 48.85 48.15 +0.09 +0.19% 23.51M 15:59:59  
  AMD 37.52 37.96 36.58 +0.81 +2.21% 67.57M 15:59:59  
  Amazon.com 1,753.11 1,775.00 1,747.32 -24.89 -1.40% 2.98M 15:59:59  
  Nevsun 4.440 4.470 4.440 0.000 0.00% 0 07/03  

Eyepoint Pharmaceuticals Inc Company Profile

IndustryBiotechnology & Drugs
SectorHealthcare
Employees

55

Equity Type

ORD

Eyepoint Pharmaceuticals, Inc., formerly pSivida Corp, develops drug delivery products primarily for the treatment of chronic eye diseases. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert. Medidur is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (posterior segment uveitis). ILUVIEN is an injectable micro-insert that provides treatment of DME from a single injection. Retisert is an implant that provides treatment of posterior segment uveitis. Its product development program is focused on utilizing its two technology platforms, Durasert and Tethadur, to deliver drugs and biologics to treat chronic diseases.

Read More

Start Trading With Top Industry Brokers

Brokers Regulation Minimum Deposit
Securities Investor Protection Corporation (United States) $0 Start Trading
National Futures Association (United States), Financial Industry Regulatory Authority (United States), Securities Investor Protection Corporation (United States) $500 Start Trading
U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States) $0 Start Trading
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

EYPT Comments

Write your thoughts about Eyepoint Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Devin Wiggins
Devin Wiggins Dec 26, 2015 3:14AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I feel as of today 12-26-15 this is a stock to watch as you've bought it. I'm watching mines but might sell when I'm in the green.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email